Home / Health / Teva Recalls Over 580,000 Blood Pressure Pill Bottles Due to Cancer Risk
Teva Recalls Over 580,000 Blood Pressure Pill Bottles Due to Cancer Risk
30 Oct
Summary
- Teva Pharmaceuticals recalls 580,844 bottles of Prazosin Hydrochloride capsules
- Tests showed capsules had high levels of cancer-causing chemicals
- Recall initiated on October 7, 2025 and classified as Class II
On October 30, 2025, it was reported that pharmaceutical company Teva Pharmaceuticals USA Inc. has initiated a voluntary recall for over 580,000 bottles of blood pressure medication due to the presence of potentially cancer-causing chemicals.
According to the Food and Drug Administration's enforcement report, Teva recalled a total of 580,844 bottles of Prazosin Hydrochloride capsules that were distributed nationwide. The recall was prompted after tests showed the capsules, available in 1 mg, 2 mg, and 5 mg doses, had "above acceptable intake limits" for an impurity called N-nitroso Prazosin impurity C, which is linked to cancer.
The recall was classified as a "Class II" by the FDA on October 24, 2025, meaning the product "may cause temporary or medically reversible adverse health consequences," or where the probability of serious adverse health consequences is remote. Teva's Health Hazard Assessment determined the overall harm to patients is considered to be medium.
Prazosin, also sold under the brand name Minipress, is an alpha-blocker used to treat hypertension. The recall affects only certain lots of the medication, with a full list of impacted lot codes available. Teva Pharmaceuticals has not yet responded to requests for comment on the matter.
